Explore CanVasc and its affiliated centers across Canada
CanVasc is the Canadian network for research on vasculitides. It was created in November 2010 by Drs. Pagnoux, Carette and Khalidi. The first task was to identify referral medical centers and physicians across Canada with expertise in vasculitis and who were willing to be part of this new research group (core members). Among its several other aims, important ones are to help conduct studies on vasculitis, provide support and educational material on vasculitides for physicians and other health care professionals and, eventually, optimize the therapeutic management of patients with these rare diseases.
CLICK HERE for more information on CanVasc.
CLICK HERE for more information on national CanVasc meetings
CanVasc recommendations for the management of ANCA-associated vasculitides
One of the objectives of CanVasc is too harmonize and optimize the treatment of patients with vasculitides and, eventually, improve their outcomes, wherever they live in Canada. The development of recommendations will help achieve this goal. Starting in 2013, CanVasc core members had been working hard to develop this first Canadian recommendations for the management of ANCA-associated vasculitides. They have been published in November 2015 in the Journal of Rheumatology (link HERE), with an executive summary in the Canadian Journal of Kidney Health and Disease (link HERE).
The teaching CanVasc CAVALI book has been distributed!
CanVasc printed out in March 2017 its first educational book on vasculitides, based on practical clinical case-scenarios, the CAVALI book (CanVasc learning initiative). Batches of books, free for residents and physicians, have beeb sent to every local CanVasc core members. An updated version of the book will be printed out in the Summer 2018.
You can download, by clicking here, the first 8 pages of the book.
Review studies on vasculitis actively recruiting in Canada
Several prospective studies on vasculitis are ongoing across the world, including in several Canadian centers. Have a brief overview of these latter ones, including ARAMIS, CUTIS, ADVOCATE, ABROGATE, DCVAS, BrainWorks and TAPIR on the study webpage and determine whether your patients could participate in any of them.
PATIENTS can also ENROLL THEMSELVES directly into the VCRC contact registry or the V-PPRN research network! Several studies are ongoing and rolling already with the active participation of patients leaving in North America, including some studies led by CanVasc researchers! See the links to these registry and network and get more information on this very innovative way to conduct patient-oriented research on the Link page.
Update your knowledge on vasculitis with CanVasc online materials
Health Canada now also approves tocilizumab for the treatment of GCA. October 2017.
FDA approves tocilizumab for the treatment of GCA. June 2017.
ARChiVe: the largest cohort of children with GPA or MPA, led by Canadian pediatricians. October 2016.
EULAR/EUVAS recommendations for ANCA-associated vasculitis. July 2016.
PR3-ANCA+ patients, especially relapsers, achieve remission with rituximab more often than with cyclophosphamide. December 2015
How the classification of vasculitides can help and impact their therapeutic management. June 2015
Download some presentations given by CanVasc members at conferences and meetings:
go to the Meeting page
Become a CanVasc member
If you are a health care provider interested in vasculitis and CanVasc activities, you can register by simply sending us an email (firstname.lastname@example.org), specifying your name, surname, profession, address and full affiliations. At this time, membership is free and does not imply anything (please note that core, associated and affiliated member status is for physicians already identified by the CanVasc bureau).
You may receive occasional information by email on the CanVasc meetings or studies. CanVasc is a non-profit scientific network. You will not receive any unsollicited mailing from other companies or groups.